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Cloned mouse S-subtype opioid receptor (DORl) was expressed in Xenopus oocytes to study the signal tr~~uction. Opioid ii-agonists evoked 
a calcium-dependent chloride current in oocytes injected with mRNA derived from DORI, together with that from the a subunit of G,l. The 
S-agonist-induced current was blocked by naltrindol, a &specific antagonist. The ii-agonist evoked no or very weak currents in oocytes with the 
a subunit of G, or G,. These findings indicate the functional coupling between the opioid &receptor and phospholipase C through an activation 
of Gi. 
&Opioid receptor; Pertussis toxin; GTP-binding protein; Signal transduction; Phospholipase C; Xenopus oocyte 
1. INTRODUCTION 
The Xenopus oocyte expression system has been 
widely used for studying signal transduction mecha- 
nisms of cloned receptors. In addition to ionotropic 
receptors [1,2], metabotropic receptors coupled to cal- 
cium-dependent chloride channel activation through 
GTP-binding protein (G-protein) and phospholipase C 
[3,4] are also good targets for electrophysiological stud- 
ies. Recent studies reported that most of receptor (G- 
protein-linked)-mediated phopholipase C activation is 
mediated by pertussis toxin-insensitive G-proteins such 
as G, [5-S]. However, little is known of ~ntribution of 
pertussis toxin-sensitive G-proteins, such as Gi or G, to 
receptor-mediated phospholipase C activation. We have 
reported that the kyotorphin (a neuropeptide) receptor 
coupled to Gil mediates phospholipase C activation, 
from reconstitution experiments using receptor in syn- 
aptic membranes and purified G-proteins [9]. On the 
other hand, we have also demonstrated that the stimula- 
tion of opioid K-receptor coupled to inhibition of intrin- 
sic G,l or Gi2 activity [lo], mediates inhibition of phos- 
pholipase C activity in guinea pig cerebellar membranes 
[11,12]. Thus, it is likely that Gi is positively coupled to 
stimulation of phospholipase C activity at least in syn- 
aptic membranes. 
pressing this receptor [14]. Although there is a prelimi- 
nary report that the opioid &receptor is possibly cou- 
pled to intracellular Ca2’ mobilization, G-protein 
involvement in such a phospholipase C activation re- 
mains to be clarified [15]. Here we report the opioid 
~-re~ptor-mediate phospholipase C activation 
through Gi, using the oocyte expression system com- 
bined with G-protein ‘reconstitution’ methods. 
2. MATERIALS AND METHODS 
2.1. Materials 
Opioid agonists used were [D-~~,n-Leu’~nkeph~in-Thr 
(DSLET), [o-Pen2.‘]~kephalin (DPDPE), [o-Ala*,MePhe4,Gly501~ 
enkephalin (DAMGO) from BACHEM (Bubendorf, Switzerland) and 
U-69593 (Upjohn, Japan). The opioid antagonist, naltrindol (NTI) 
was a gift from Dr. Nagase (Toray, Japan). Inositol 1,4,5- tri- 
phosphate (IP,) was purchased from Sigma (St. Louis, USA). cDNA 
clones used were mouse 6 opioid receptor, DORI [14] from Dr. C. 
Evans (UCLA, USA), cz subunits of rat G,l and G, (G,la and G,a, 
respectively) [16] from Dr. H. Ito (Tokyo Institute of Technology, 
Yokohama, Japan), rat G,a [17] from M. Simon (Califo~ia Institute 
of Technology, Pasadena, USA). 
2.2. Electrophysiological recordings in Xenopus oocytes 
The opioid S-receptor is well known to inhibit adenyl- 
ate cyclase activity in neuroblastoma x glioma hybrid 
NGl08-15 cells via the action of Gi [13]. Most recently, 
the a-receptor has been cloned from a cDNA library of 
NGlOS-15 cells and found to be functional in inhibiting 
membrane adenylate cyclase activity in COS cells ex- 
*Corresponding author. Fax: (81) (45) 785 3645. 
Xenopus laevis were anaesthetised in ice-water and a lobe of ovary 
was removed after a small incision was made in the ventral abdominal 
surface. Oocytes (stages 5 and 6, see reference [18]) were defolliculated 
at room temperature by a 3 h treatment with collagenase (2 mg/ml) 
in Ca*‘-free modified Barth’s solution (MBS). MBS contains NaCl88 
(mM), KC1 1, NaHCO, 2.38, MgSO, 0.82, CaCl, 0.41, Ca(NO& 0.33, 
Tris-HCl 7.5, pH 7.5. Oocytes were then washed and incubated at a 
constant temperature of 19°C in MBS containing streptomycin (0.1 
mg/ml) and penicillin (100 U/ml). After 24 h incubation, oocytes were 
microinjected at room temperature (24’C) with 70 nl of mRNAs 
generated by in vitro transcription primed with cap dinucleotide 
m7G(5’)ppp(5’)G using a Stratagene kit from mouse LF-opioid receptor 
(DORI, 10 ng) and from rat G,la, G,a or G,a (each 50 ng). After a 
further 2 days incubation at 19°C to allow for protein expression, 
Published by Ekevier Science Publishers B. K 311 
Volume 333, number 3 
a. b. 
FEBSLETTERS November 1993 
C. 
- J - J 
DSLET (1pM) DSLET (1pM) 
d. 
i 
li “I - -1 -
DSLET (1pM) -I 
e. 
+@I +Go 
!P L- - 4 2 A DSLET (QM) - - - 
DSLET (1rM) 
1 DSLET (1pM) --J 
IP3 (lpmole) 
Fig. 1. Typical current responses on the 6 opioid agonist, DSLET in DORl mRNA-injected oocytes at a holding potential of 0 mV. Panel a and 
b: DSLET (1 PM)-evoked outward current in oocytes co-injected without and with G,la mRNA, respectively. Panel c and d: effects of intracellularly 
injected EGTA and IP, on the DSLET-evoked current in oocytes co-injected with G&c mRNA, respectively. Left recordings in panel c and d: control 
DSLET-responses 15 min before intracellular injection, respectively. Right recordings in panel c and d: DSLET-responses 5 min after injection 
of 100 pmol EGTA or 1 pmol IP,, respectively. Panel e: DSLET-responses in oocytes co-injected with G,a (left panel) or with G,a (right panel), 
respectively. The vertical and horizontal bar represent 20 nA and 1 min, respectively. 
responses to bath application of opioid agonists were detected in 
injected Xenopus oocytes using a voltage-clamp recording. Unless 
otherwise stated, the holding potential was at 0 mV to get maximal 
response. Electrophysiological recordings were made using a conven- 
tional two-electrode voltage-clamp technique with both microelec- 
trodes filled with 3 M potassium chloride (resistance 0.5-5 MR). 
Oocytes were placed in a 0.1 ml chamber and continuously superfused 
(flow rate: 3-5 ml/min) with MBS. Electrophysiological recordings 
were performed at room temperature and only oocytes with an input 
resistance of l-5 Mf2 were used. The current-voltage relationships 
were obtained using the ‘ramp clamp’ technique as described previ- 
ously [19,20]. 
3. RESULTS 
Bath application of [n-Ser2,0-Leu’lenkephalin-Thr/ 
DSLET, a selective opioid J-agonist (62 subtype) at 1 
PM to oocytes injected with DORl mRNA showed 
weak outward currents (mean f S.E.M. = 15.9 & 5.6 
nA) at a holding potential of 0 mV in 5 preparations 
(Fig. la). There was no reproductive response on the 
second challenge of the d-agonist even at 10 PM (data 
not shown). 
When oocytes were injected with Gilcx mRNA to- 
gether with DORl, the b-agonist-responses were poten- 
tiated 2- to 4-fold (62.5 f 21.1 nA), as shown in Fig. 1 b. 
The outward current was oscillating and lasted for 2-5 
min. The evoked current was blocked by intracellular 
injection of 100 pmol EGTA, a selective calcium-ion 
chelating agent (Fig. lc), or by direct injection of 1 pmol 
of IP, 5 min prior to the opioid agonist challenge (Fig. 
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Fig. 2. Current-voltage relationship for the DSLET-evoked current. 
The data were obtained in oocytes with mRNAs of DORl and G,la, 
using the voltage ramp (300 mV/s) clamp method [19,20]. The reversal 
potential (-25 mV) is the voltage where zero current flows through the 
membrane. The inset shows the traces of DSLET-evoked currents at 
a holding potential of 0, -25 and -75 mV, respectively. 
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Id). The current was outwardly rectifying and the rever- 
sal potential was approximately -25 mV (Fig. 2), sug- 
gesting the involvement of chloride channel opening. 
All these characteristics are typical to metabotropic re- 
ceptor-mediated response through phospholipase C, 
but the current was much weaker, compared to the 
responses involving G, (or pertussis toxin-insensitive 
G-protein)-phospholipase C activation, such as mGR1 
metabotropic glutamate receptor responses (approxi- 
mately 1 PA), which have been preliminarily reported 
[21] and confirmed by ourselves (unpublished data). 
However, when mRNA of G,a: or G,a was injected into 
oocytes together with DORl mRNA, there was no de- 
tectable response (n = 5, sensitivity limit of approxi- 
mately 2 nA) or 10.3 + 3.5 nA (n = 5) to the J-agonist 
at 1 PM in 5 preparations, respectively (Fig. le). There 
was no significant difference between currents with G, 
and without any G-protein mRNA. 
As shown in Fig. 3a, the J-agonist response was com- 
pletely blocked by naltrindol (NTI), a selective &opioid 
antagonist [22], and then recovered to the initial level by 
the agonist after the wash of the antagonist. Similarly 
we tested various opioid agonists, compared to DSLET- 
response. As shown in Fig. 3b, DPDPE, another spe- 
cific d-agonist (&-subtype, see reference [22]) evoked an 
equipotent outward current, while there were no re- 
sponses with 1 ,uM DAMGO, a specific y-opioid ag- 
onist [23] or with 1 PM U69593, a specific x;--opioid 
agonist [24]. 
4. DISCUSSION 
It has been long since the possible involvement of 
pertussis toxin-sensitive G-proteins in phospholipase C 
activation was claimed [25]. Actually there are some 
reports using reconstitution experiments providing evi- 
dence that Gi is coupled to phospholipase C activation 
[9,11,26]. In the last several years, however, most accu- 
mulating findings are about the involvement of G, (or 
pertussis toxin-insensitive G-protein) in this mechanism 
[8]. This might originate from the fact that intrinsic 
activity of G, in phospholipase C activation is much 
higher than Gi, as mentioned above. Of interest is the 
possibility that Gi and G, mutually interfere with their 
functional coupling to phospholipase C. A weak &ag- 
onist response in oocytes without G-protein mRNA in- 
jection was abolished by G, mRNA injection (Fig. le). 
As endogenous G,-like G-proteins themselves might be 
partially activated (or G-proteins have their intrinsic 
activity without receptor stimulation, possibly through 
an activation by endogenous GTP) in the cell, overex- 
pressed G, might inhibit the functional coupling of Gi 
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Fig. 3. Effects of various opioid agonists and antagonist in oocytes injected with mRNAs of DORl and G,la at a holding potential of 0 mV. Agonist 
applications were performed every 20 min. Panel a: antagonism of DSLET (1 PM)-evoked outward current by 100 nM naltrindol, a S-opioid 
antagonist in the same oocyte. Panel b: no detectable ffect by 1 PM DAMGG @-agonist) or 1 PM U69593 (x-agonist) and significant outward 
currents by 100 nM DPDPE (&-agonist) or 100 nM DSLET (&!-agonist). 
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to phospholipase C, as a competitor for this enzyme. In 
this respect, it is likely that G, is not a good competitor 
for this enzyme, since there was no significant change 
in J-agonist response by its mRNA injection (Fig. le). 
It has been accepted that the opioid J-receptor medi- 
ates the closing of calcium channels in NG108-15 cells 
through the action of G, rather than Gi [27]. However, 
such a weak calcium channel activity is not detected in 
the present system without major changes of the system, 
such as mRNA (related calcium channel) injection, ion- 
balancing in the su~rfusion solution and addition of 
some agents to suppress major other ion channel activ- 
ities. Therefore, from using the present system, it is 
evident hat G, is not involved in g-agonist response. In 
addition, it is unlikely that G, has much higher intrinsic 
activity on phospholipase C in the oocyte than Gi. In the 
previous paper by Moriaty et al. [28], the direct injection 
of purified G, potentiated muscarinic acetylcholine re- 
sponse to endogenously expressed muscarinic receptors 
(it has been characterized to be coupled to G, or pertus- 
sis toxin-insensitive G-proteins) in the oocyte. As G, 
had not yet been characterized to be coupled to phos- 
pholipase C at that time, the contamination of G, or 
related G-proteins in the Go-preparation might not be 
excluded, although they proved it to be devoid of Gi. 
However, it remains to be clarified whether or not, if 
any, how much G, is involved in mediating phospholip- 
ase C activation. 
The major findings in this report are as follows: (I) 
the opioid &receptor activates phospholipase C 
through the action of Gil, and it does inhibit adenylate 
cyclase in the same manner; (2) Gil is also involved in 
phospholipase C activation, but the intrinsic activity to 
activate this enzyme is less potent, compared to G,; (3) 
the contribution of G, to the activation of phospholip- 
ase C remains unclear, but this G-protein is not in- 
volved in the opioid S-receptor-mediated activation of 
phospholipase C. The direct evidence of a-receptor cou- 
pling to phospholipase C activation through Gi, by Gi- 
reconstitution experiments in mammalian cell mem- 
branes expressing DOR 1, are in progress in our labora- 
tory. 
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